Paediatric plaque psoriasis

Active Ingredient: Ixekizumab

Indication for Ixekizumab

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Therapeutic intent: Curative procedure

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments:

For patients weighting >50 kg 160 mg at Week 0 and thereafter 80 mg every 4 weeks, and for patients weighting 25-50 kg 80 mg at Week 0 and thereafter 40 mg every 4 weeks

For:

Dosage regimens

Regimen A, in case that patient age in years is ≥ 6 and patient weight is > 50 kg

Subcutaneous, 160 milligrams ixekizumab, one dose, over the duration of 4 weeks. Afterwards, subcutaneous, 80 milligrams ixekizumab, once every 4 weeks.

Regimen B, in case that patient age in years is ≥ 6 and patient weight is ≥ 25 kg and patient weight is ≤ 50 kg

Subcutaneous, 80 milligrams ixekizumab, one dose, over the duration of 4 weeks. Afterwards, subcutaneous, 40 milligrams ixekizumab, once every 4 weeks.

Detailed description

Efficacy and safety data is not available in children below the age of 6 years. Available data do not support a posology below a body weight of 25 kg.

The recommended dose given by subcutaneous injection in children is based on the following weight categories:

Children's body
weight
Recommended starting
dose (week 0)
Recommended dose every
4 weeks (Q4W) thereafter
Greater than 50 kg160 mg (two 80 mg injections)80 mg
25 to 50 kg80 mg40 mg

Ixekizumab is not recommended for use in children with a body weight below 25 kg. Paediatric body weights must be recorded and regularly re-checked prior to dosing.

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.

Dosage considerations

If possible, areas of the skin that show psoriasis should be avoided as injection sites.

Active ingredient

Ixekizumab

Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (<3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL-17A by ixekizumab inhibits these actions.

Read more about Ixekizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.